InspireMD Inc. (NSPR)

InspireMD reported a 39% year-over-year revenue growth in Q3 2025, driven by the CGuard Prime U.S. launch. The company participated in the 25th Annual Needham Virtual Healthcare Conference in April 2026. A shareholder investigation was announced in April 2026. A voluntary U.S. recall of the CGuard Prime delivery system occurred in May 2026, leading to the withdrawal of 2026 revenue guidance. The FDA approved the CGUARDIANS III pivotal study for SwitchGuard in May 2026. Q1 2026 revenue increased by 122% year-over-year, but the company disclosed doubt about its ability to continue as a going concern. Insider buying occurred in May 2026, with directors Gary S. Roubin and Scott Ward purchasing shares. InspireMD is scheduled to participate in the Bank of America Securities 2026 Global Healthcare Conference.

The provided search results do not explicitly detail demand seasonality for InspireMD, Inc.'s products and services. Demand is generally driven by the prevalence of carotid artery disease and stroke, as well as the adoption of new technologies and clinical guidelines. The company's focus on expanding its U.S. commercial team and advancing clinical trials suggests a continuous effort to drive adoption and market penetration rather than responding to seasonal peaks.

InspireMD, Inc. is a medical device company specializing in MicroNet stent platform technology for treating complex vascular and coronary diseases. Their flagship product is the CGuard Carotid Embolic Prevention System (EPS), which combines a self-expanding nitinol stent with a MicroNet mesh to prevent embolic events. Other products include the CGuard Prime Carotid Stent System, MGuard Prime Embolic Protection System, and SwitchGuard Neuroprotection System.

InspireMD has a global presence, commercializing its products in the United States, Germany, Italy, Russia, Poland, and other international markets. The company has sold over 60,000 CGuard implants globally. Its headquarters are in Miami, Florida, with offices in Tel Aviv, Israel.

InspireMD's brand reputation has been influenced by the FDA approval and U.S. launch of the CGuard Prime Carotid Stent System, supported by clinical evidence. However, the voluntary U.S. recall of the CGuard Prime delivery system negatively impacted its reputation and financial outlook. The company's disclosure of doubt about its ability to continue as a going concern and a shareholder investigation also affected its reputation.

InspireMD has 49 institutional owners and shareholders holding 23,160,476 shares, representing approximately 44.78% of the stock. Major institutional owners include Rosalind Advisors, Inc., Nantahala Capital Management, LLC, and Standard Life Aberdeen plc. Marvin Slosman, President, CEO & Director, holds a 5.18% beneficial stake. Director Gary S. Roubin directly owns 834,478 shares, and Director Scott Ward holds 237,096 shares.